Dalbavancin_COA_18398_MedChemExpress
雷帕霉素-SDS-MedChemExpress
Inhibitors, Agonists, Screening LibrariesSafety Data Sheet Revision Date:Jan.-07-2019Print Date:Jan.-07-20191. PRODUCT AND COMPANY IDENTIFICATION1.1 Product identifierProduct name :RapamycinCatalog No. :HY-10219CAS No. :53123-88-91.2 Relevant identified uses of the substance or mixture and uses advised againstIdentified uses :Laboratory chemicals, manufacture of substances.1.3 Details of the supplier of the safety data sheetCompany:MedChemExpress USATel:609-228-6898Fax:609-228-5909E-mail:sales@1.4 Emergency telephone numberEmergency Phone #:609-228-68982. HAZARDS IDENTIFICATION2.1 Classification of the substance or mixtureGHS Classification in accordance with 29 CFR 1910 (OSHA HCS)Flammable liquids (Category 4), H2272.2 GHS Label elements, including precautionary statementsPictogram No data availableSignal word WarningHazard statement(s)H227 Combustible liquid.Precautionary statement(s)P210 Keep away from heat ⁄sparks ⁄open flames ⁄hot surfaces. - No smoking.P280 Wear protective gloves ⁄ protective clothing ⁄ eye protection ⁄ face protection.P370 + P378 In case of fire: Use dry sand, dry chemical or alcohol-resistant foam for extinction.P403 + P235 Store in a well-ventilated place. Keep cool.P501 Dispose of contents ⁄ container to an approved waste disposal plant.2.3 Other hazardsNone.3. COMPOSITION/INFORMATION ON INGREDIENTS3.1 SubstancesSynonyms:SirolimusFormula:C51H79NO13Molecular Weight:914.17CAS No. :53123-88-94. FIRST AID MEASURES4.1 Description of first aid measuresEye contactRemove any contact lenses, locate eye-wash station, and flush eyes immediately with large amounts of water. Separate eyelids with fingers to ensure adequate flushing. Promptly call a physician.Skin contactRinse skin thoroughly with large amounts of water. Remove contaminated clothing and shoes and call a physician.InhalationImmediately relocate self or casualty to fresh air. If breathing is difficult, give cardiopulmonary resuscitation (CPR). Avoid mouth-to-mouth resuscitation.IngestionWash out mouth with water; Do NOT induce vomiting; call a physician.4.2 Most important symptoms and effects, both acute and delayedThe most important known symptoms and effects are described in the labelling (see section 2.2).4.3 Indication of any immediate medical attention and special treatment neededTreat symptomatically.5. FIRE FIGHTING MEASURES5.1 Extinguishing mediaSuitable extinguishing mediaUse water spray, dry chemical, foam, and carbon dioxide fire extinguisher.5.2 Special hazards arising from the substance or mixtureDuring combustion, may emit irritant fumes.5.3 Advice for firefightersWear self-contained breathing apparatus and protective clothing.6. ACCIDENTAL RELEASE MEASURES6.1 Personal precautions, protective equipment and emergency proceduresUse full personal protective equipment. Avoid breathing vapors, mist, dust or gas. Ensure adequate ventilation. Evacuate personnel to safe areas.Refer to protective measures listed in sections 8.6.2 Environmental precautionsTry to prevent further leakage or spillage. Keep the product away from drains or water courses.6.3 Methods and materials for containment and cleaning upAbsorb solutions with finely-powdered liquid-binding material (diatomite, universal binders); Decontaminate surfaces and equipment by scrubbing with alcohol; Dispose of contaminated material according to Section 13.7. HANDLING AND STORAGE7.1 Precautions for safe handlingAvoid inhalation, contact with eyes and skin. Avoid dust and aerosol formation. Use only in areas with appropriate exhaust ventilation.7.2 Conditions for safe storage, including any incompatibilitiesKeep container tightly sealed in cool, well-ventilated area. Keep away from direct sunlight and sources of ignition.Recommended storage temperature:Powder-20°C 3 years4°C 2 years* The compound is unstable in solutions, freshly prepared is recommended.Shipping at room temperature if less than 2 weeks.7.3 Specific end use(s)No data available.8. EXPOSURE CONTROLS/PERSONAL PROTECTION8.1 Control parametersComponents with workplace control parametersThis product contains no substances with occupational exposure limit values.8.2 Exposure controlsEngineering controlsEnsure adequate ventilation. Provide accessible safety shower and eye wash station.Personal protective equipmentEye protection Safety goggles with side-shields.Hand protection Protective gloves.Skin and body protection Impervious clothing.Respiratory protection Suitable respirator.Environmental exposure controls Keep the product away from drains, water courses or the soil. Cleanspillages in a safe way as soon as possible.9. PHYSICAL AND CHEMICAL PROPERTIES9.1 Information on basic physical and chemical propertiesAppearance White to off-white (Solid)Odor No data availableOdor threshold No data availablepH No data availableMelting/freezing point No data availableBoiling point/range No data availableFlash point No data availableEvaporation rate No data availableFlammability (solid, gas)No data availableUpper/lower flammability or explosive limits No data availableVapor pressure No data availableVapor density No data availableRelative density No data availableWater Solubility No data availablePartition coefficient No data availableAuto-ignition temperature No data availableDecomposition temperature No data availableViscosity No data availableExplosive properties No data availableOxidizing properties No data available9.2 Other safety informationNo data available.10. STABILITY AND REACTIVITY10.1 ReactivityNo data available.10.2 Chemical stabilityStable under recommended storage conditions.10.3 Possibility of hazardous reactionsNo data available.10.4 Conditions to avoidNo data available.10.5 Incompatible materialsStrong acids/alkalis, strong oxidising/reducing agents.10.6 Hazardous decomposition productsUnder fire conditions, may decompose and emit toxic fumes.Other decomposition products - no data available.11.TOXICOLOGICAL INFORMATION11.1 Information on toxicological effectsAcute toxicityClassified based on available data. For more details, see section 2Skin corrosion/irritationClassified based on available data. For more details, see section 2Serious eye damage/irritationClassified based on available data. For more details, see section 2Respiratory or skin sensitizationClassified based on available data. For more details, see section 2Germ cell mutagenicityClassified based on available data. For more details, see section 2CarcinogenicityIARC: No component of this product present at a level equal to or greater than 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.ACGIH: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by ACGIH.NTP: No component of this product present at a level equal to or greater than 0.1% is identified as a anticipated or confirmed carcinogen by NTP.OSHA: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by OSHA.Reproductive toxicityClassified based on available data. For more details, see section 2Specific target organ toxicity - single exposureClassified based on available data. For more details, see section 2Specific target organ toxicity - repeated exposureClassified based on available data. For more details, see section 2Aspiration hazardClassified based on available data. For more details, see section 212. ECOLOGICAL INFORMATION12.1 ToxicityNo data available.12.2 Persistence and degradabilityNo data available.12.3 Bioaccumlative potentialNo data available.12.4 Mobility in soilNo data available.12.5 Results of PBT and vPvB assessmentPBT/vPvB assessment unavailable as chemical safety assessment not required or not conducted.12.6 Other adverse effectsNo data available.13. DISPOSAL CONSIDERATIONS13.1 Waste treatment methodsProductDispose substance in accordance with prevailing country, federal, state and local regulations.Contaminated packagingConduct recycling or disposal in accordance with prevailing country, federal, state and local regulations.14. TRANSPORT INFORMATIONDOT (US)This substance is considered to be non-hazardous for transport.IMDGThis substance is considered to be non-hazardous for transport.IATAThis substance is considered to be non-hazardous for transport.15. REGULATORY INFORMATIONSARA 302 Components:No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.SARA 313 Components:This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.SARA 311/312 Hazards:No SARA Hazards.Massachusetts Right To Know Components:No components are subject to the Massachusetts Right to Know Act.Pennsylvania Right To Know Components:No components are subject to the Pennsylvania Right to Know Act.New Jersey Right To Know Components:No components are subject to the New Jersey Right to Know Act.California Prop. 65 Components:This product does not contain any chemicals known to State of California to cause cancer, birth defects, or anyother reproductive harm.16. OTHER INFORMATIONCopyright 2019 MedChemExpress. The above information is correct to the best of our present knowledge but does not purport to be all inclusive and should be used only as a guide. The product is for research use only and for experienced personnel. It must only be handled by suitably qualified experienced scientists in appropriately equipped and authorized facilities. The burden of safe use of this material rests entirely with the user. MedChemExpress disclaims all liability for any damage resulting from handling or from contact with this product.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。
酒石酸卡巴拉汀的产品说明书
参考文献：
[1]. Kurz A, Farlow M, Lefèvre G. Pharmacokinetics of a novel transdermal rivastigmine patch for the treatment of Alzheimer's disease: a review. Int J Clin Pract. 2009 May;63(5):799-805.
中文别名：
酒石酸卡巴拉汀;(S)-N-乙基-N-甲基氨基甲酸-3-[(1-二甲氨基)乙基]苯酯酒石酸盐;卡巴拉汀或利斯的明酒石酸盐;L-酒石酸卡巴拉汀;2,3',4-三溴二苯醚;N-乙基甲基氨基甲酰氯;Rivastigmine L-Tartrate L-酒石酸卡巴拉汀;酒石酸卡巴拉汀 USP标准品;酒石酸卡巴拉汀Rivastigmine tartrate;酒石酸卡巴拉汀标准品;酒石酸卡巴拉汀氢 EP标准品;酒石酸利凡斯的明;卡巴拉丁;卡巴拉汀酒石酸盐;重酒石酸卡巴拉汀;重酒石酸利凡斯的明;(S)-N-乙基-N-甲基氨基甲酸-3-[(S)-1-(二甲氨基)乙基]苯酯酒石酸盐;氘代重酒石酸利斯的明-d6;酒石酸卡巴拉汀 中文别名：卡巴拉汀或利斯的明酒石酸盐;酒石酸利伐斯的明;酒石酸利瓦斯汀;利斯的明酒石酸盐;卡巴拉汀重酒石酸盐
熔点
123-1250C
分子式
C18H28N2O8
分子量
400.423
闪点
145ºC
精确量
400.18457
PSA
147.84
LogP
0.6371
HPLC法测定黄藤素栓中盐酸巴马汀的含量
ＨＰＬＣ法测定黄藤素栓中盐酸巴马汀的含量目的：建立黄藤素栓中盐酸巴马汀的含量测定方法。
方法：采用高效液相色谱法（HPLC），以C18柱为色谱柱；以乙腈-0.4%磷酸溶液（32:68）为流动相；柱温40℃；检测波长为345nm测定。
结果：盐酸巴马汀在24.74μg/ml～98.96μg/ml 的浓度范围内与峰面积呈良好的线性关系（r=0.9999），平均回收率为99.50%，RSD%为0.64%（n=9）。
结论：HPLC法快速、准确、重现性好，能用于黄藤素栓中盐酸巴马汀的含量测定。
标签：盐酸巴马汀黄藤素栓HPLC法含量测定1 仪器与试药仪器：高效液相色谱仪（SPD-10A VP型可见—紫外检测器；SPD-10ATVP 溶剂输送泵），日本岛津制造所。
紫外可见分光光度计（UV-2550），日本岛津制造所。
试药：盐酸巴马汀对照品（中国药品生物制品检定所提供）；黄藤素栓、黄藤素阴性栓（公司制备）；乙腈为色谱纯；水为去离子水；其他试剂均为分析纯。
2 方法与结果2.1 色谱条件以C18柱（迪马；250mm×4.6mm；5μm）为色谱柱；以乙腈-0.4%磷酸溶液（32:68）为流动相；柱温40℃；检测波长为345nm；流速1.0ml/min。
理论塔板数按盐酸巴马汀峰计算不低于5000。
2.2 测定法取样品切碎，取1.5g，精密称定，置100ml量瓶中，加水适量，置温水浴中使溶解，放置至室温，加水稀释至刻度，摇匀，精密量取1ml，置10ml 量瓶中，加流动相稀释至刻度，摇匀，滤过，精密量取续滤液10μl注入色谱仪，记录色谱图；取盐酸巴马汀对照品12.5mg，精密称定，置25ml量瓶中，加水溶解，摇匀，精密量取1ml，置10ml量瓶中，加流动相稀释至刻度，摇匀，同法测定，按外标法以峰面积计算，即得。
2.3 检测波长的选择取盐酸巴马汀对照品适量，用水溶解并稀释制成1ml 中约含10μg的溶液，在190～600nm范围内进行紫外扫描。
盐酸伊达比星原料药抗肿瘤类及免疫抑制剂
武汉贝尔卡生物医药有限公司产品简介
中文品名 盐酸伊达比星
CAS 号 57852-57-0
英文品名 Idarubicin HCl
产品编号 MB1121
盐酸伊达比星
分子式：C 26H 27NO 9.
HCl 分子量：533.95
物理性状及指标：
外观：……………………红橙色或红棕色粉末
溶解性：…………………溶于甲醇，微溶于乙醇和水，几乎不溶于丙酮和乙醚
含量：……………………960~1030ug/mg
用途及描述：科研试剂，广泛应用于分子生物学，药理学等科研方面。
本药为蒽环类抗生素，有抗有丝分裂和细胞毒作用。
盐酸伊达比星为柔红霉素类似物，因蒽环第4位缺少一个甲氧基，故比柔红霉素的脂溶性高，更易透过细胞膜。
盐酸伊达比星可抑制核酸合成，干扰拓扑异构酶Ⅱ
储存条件：2-8℃，避光防潮密闭干燥。
注意：我司产品为非无菌包装，若用于细胞培养，请提前做预处理，除去热原细菌，否则会导致染菌。
以上数据仅供参考交流之用。
盐酸伊达比星的溶解性，盐酸伊达比星在水中的溶解性，盐酸伊达比星在生理盐水中的溶解性，盐酸伊达比星在PBS 缓冲液中的溶解性，盐酸伊达比星在DMSO 、乙醇等有机溶剂中的溶解性，盐酸伊达比星在细胞实验方面的应用，盐酸伊达比星在大鼠等动物实验方面的应用。
FDA批准的放射性药物都有哪些？
FDA批准的放射性药物都有哪些？展开全文中华医学会核医学分会放射性药物学组整理1、药物名称：Carbon-11 choline（11C-胆碱）生产商：Mayo Clinic 商品名：—用途：前列腺癌复发诊断2、药物名称：Carbon-14 urea（14C-尿素）生产商：Kimberly-Clark 商品名：PYtest用途：胃中幽门螺杆菌感染诊断3、药物名称：Fluorine-18 florbetaben（18F-AV1）生产商：Piramal Imaging 商品名：Neuraceq™用途：阿尔茨海默（AD）患者和痴呆患者评价4、药物名称：Fluorine-18florbetapir（18F-AV45）生产商：Eli Lilly 商品名：Amyvid™用途：阿尔茨海默症诊断与治疗5、药物名称：Fluorine-18sodium fluoride（18F-氟化钠）生产商：Various 商品名：—用途：成骨能力的骨显像剂6、药物名称：Fluorine-18fludeoxyglucose（18F-FDG）生产商：Various 商品名：—用途：肿瘤、癫痫病灶糖代谢异常检测7、药物名称：Fluorine-18flutemetamol（18F-PIB）生产商：GE Healthcare 商品名：Vizamyl用途：阿尔茨海默（AD）患者和痴呆患者评价8、药物名称：Gallium-67 citrate（67Ga-柠檬酸）生产商：Lantheus MedicalImaging、Mallinckrodt商品名：—用途：霍奇金病、淋巴瘤、支气管癌以及一些急性炎症病变诊断9、药物名称：Indium-111capromab pendetide（111In-卡罗单抗喷地肽）生产商：AytuPharmaceuticals 商品名：ProstaScint®用途：前列腺癌患者、前列腺癌术后高度怀疑转移患者的检测10、药物名称：Indium-111 chloride（111In-氯化铟）生产商：GE Healthcare、Mallinckrodt 商品名：Indiclor™用途：用于放射性标记11、药物名称：Indium-111 pentetate（111In-DTPA）生产商：GE Healthcare 商品名：—用途：放射性核素脑池造影12、药物名称：Indium-111oxyquinoline（111In-羟基喹啉）生产商：GE Healthcare 商品名：—用途：用于自体白细胞标记，炎症及感染的诊断13、药物名称：Indium-111pentetreotide（111In-奥曲肽）生产商：Mallinckrodt 商品名：Octreoscan™用途：原发性和转移性内神经分泌肿瘤生长抑素受体定位14、药物名称：Iodine I-123iobenguane（123I-MIBG）生产商：GE Healthcare 商品名：AdreView™用途：原发或转移性嗜铬细胞瘤或神经母细胞瘤的辅助诊断15、药物名称：Iodine I-123 ioflupane（123I-氟潘）生产商：GE Healthcare 商品名：DaTscan™用途：对疑似帕金森症患者的评估16、药物名称：Iodine I-123sodium iodide capsules（123I-碘化钠胶囊）生产商：Cardinal Health、Mallinckrodt 商品名：—用途：甲状腺功能及形态学评价17、药物名称：Iodine I-125 humanserum albumin（125I-人血清白蛋白）生产商：IsoTex Diagnostics 商品名：Jeanatope用途：全血及血浆容量测定18、药物名称：Iodine I-125iothalamate（125I-酞酸盐）生产商：IsoT ex Diagnostics商品名：Glofil-125用途：肾小球滤过率的评价19、药物名称：Iodine I-131 humanserum albumin（131I-人血清白蛋白）生产商：IsoTex Diagnostics 商品名：Megatope用途：全血及血浆量、心脏输出、心脏及肺血容量、蛋白质周转研究、脑肿瘤定位等20、药物名称：Iodine I-131sodium iodide（131I-碘化钠）生产商：DRAXIMAGE、Mallinckrodt 商品名：HICON™用途：甲状腺疾病的诊断与治疗21、药物名称：MolybdenumMo-99 generator（钼锝发生器）生产商：GE Healthcare、Lantheus MedicalImaging、Mallinckrodt商品名：DRYTEC™、T echnelite、UltraTechneKow®DTE用途：放射性药物的制备22、药物名称：Nitrogen-13 ammonia（13N-氨水）生产商：Various 商品名：—用途：心肌灌注评价冠状动脉疾病23、药物名称：Radium-223 dichloride（223Ra-二氯化镭）生产商：Bayer HealthCarePharmaceuticalsInc. 商品名：Xofigo®用途：去势性前列腺癌治疗24、药物名称：Rubidium-82 chloride（82Ru-氯化铷）生产商：Bracco Diagnostics 商品名：Cardiogen-82®用途：心肌灌注显像剂25、药物名称：Samarium-153lexidronam（153Sm-EDTMP）生产商：Lantheus MedicalImaging 商品名：Quadramet®用途：减轻骨转移患者的疼痛26、药物名称：Strontium-89 chloride（89Sr-氯化锶）生产商：GE Healthcare商品名：MetastronTM用途：减轻骨转移患者的疼痛27、药物名称：T echnetium-99mbicisate（99mT c-ECD）生产商：Lantheus MedicalImaging 商品名：Neurolite®用途：脑卒中患者卒中的诊断与治疗28、药物名称：Technetium-99mdisofenin（99mTc-地索芬宁）生产商：Pharmalucence 商品名：Hepatolite®用途：急性胆囊炎诊断29、药物名称：Technetium-99mexametazine（99mTc-HMPAO）生产商：GE Healthcare 商品名：C eretec™用途：脑卒中患者血脑灌注、白细胞标记显像用用于腹腔感染及肠道炎症定位30、药物名称：T echnetium-99mmacroaggregatedalbumin （99mT c-MAA）生产商：DRAXIMAGE 商品名：—用途：肺灌注评价、腹静脉分流畅通性评价31、药物名称：Technetium-99mmebrofenin（99mT c-甲溴苯宁）生产商：Bracco Diagnostics、Pharmalucence 商品名：Choletec®用途：肝胆显像剂32、药物名称：Technetium-99mmedronate（99mTc-MDP）生产商：DRAXIMAGE、GE Healthcare、Pharmalucence 商品名：MDP-25、MDP Multidose用途：骨显像剂33、药物名称：Technetium-99mmertiatide（99mTc-MAG3）生产商：Mallinckrodt 商品名：TechnescanMAG3TM用途：肾动态显像34、药物名称：Technetium-99moxidronate（99mT c-HDP）生产商：Mallinckrodt 商品名：Tec hnescan™HDP用途：骨显像剂35、药物名称：Technetium-99mpentetate（99mT c-DTPA）生产商：DRAXIMAGE 商品名：—用途：脑显像、肾显像36、药物名称：T echnetium-99mpyrophosphate（99mTc-PYP）生产商：Mallinckrodt、Pharmalucence 商品名：Technescan™、PYP™用途：骨显像、心脏显像剂、血池显像剂37、药物名称：Technetium-99m redblood cells（99mT c-红细胞）生产商：Mallinckrodt 商品名：UltraTag™用途：血池造影、消化道出血定位38、药物名称：T echnetium-99msestamibi（99mTc-MIBI）生产商：Cardinal Health、DRAXIMAGE、Lantheus MedicalImaging、Mallinckrodt、Pharmalucence商品名：Cardiolite®用途：心肌灌注，用于检测缺血、评价心机功能，乳腺成像39、药物名称：Technetium-99msodium pertechnetate （99mT c-高锝酸钠）生产商：GE Healthcare、Lantheus MedicalImaging、Mallinckrodt商品名：—用途：脑显像、甲状腺显像、胎盘定位、膀胱显像等40、药物名称：Technetium-99msuccimer（99mT c-DMSA）生产商：GE Healthcare 商品名：—用途：肾显像41、药物名称：Technetium-99msulfur colloid（99mT c-硫胶体）生产商：Pharmalucence 商品名：—用途：肝、脾、骨髓显像等42、药物名称：Technetium-99mtetrofosmin（99mTc-替曲膦）生产商：GE Healthcare 商品名：MyoviewTM用途：心肌灌注剂43、药物名称：Technetium-99mtilmanocept（99mTc-替马诺噻）生产商：NavideaBiopharmaceuticals,Inc. 商品名：Lymphoseek®用途：淋巴结定位44、药物名称：Thallium-201chloride（201Tl-氯化铊）生产商：GE Healthcare、Lantheus MedicalImaging、Mallinckrodt商品名：—用途：心肌灌注显像45、药物名称：Xenon-133 gas（133Xe气体）生产商：Lantheus MedicalImaging 商品名：—用途：肺功能评估与肺显像、脑血流评估46、药物名称：Yttrium-90chloride（90Y-氯化钇）生产商：MDS Nordion、Eckert＆ZieglerNuclitec商品名：—用途：放射性标记47、药物名称：Yttrium-90ibritumomab tiuxetan（90Y-替伊莫单抗）生产商：SpectrumPharmaceuticals商品名：Zevalin®用途：非霍奇金氏淋巴瘤治疗截止至2015年8月1日。
达格列净联合双歧杆菌三联活菌对糖尿病性腹泻患者的疗效及血糖水平的影响
DOI：10.16658/ki.1672-4062.2024.01.005达格列净联合双歧杆菌三联活菌对糖尿病性腹泻患者的疗效及血糖水平的影响谢永秀1，张响荣2，张秀林11.宁化县总医院内分泌科，福建三明365400；2.宁化县总医院消化内科，福建三明365400[摘要]目的探讨达格列净联合双歧杆菌三联活菌治疗糖尿病性腹泻的临床效用。
方法选取2021年1月—2022年12月宁化县总医院收治的糖尿病性腹泻患者80例作为研究对象，按照随机数表法分为对照组和观察组，每组40例。
对照组采用二甲双胍+达格列净+蒙脱石散治疗，观察组在此基础上增加双歧杆菌三联活菌治疗。
观察和比较两组患者疗效、血糖水平、肠道菌群。
结果观察组总有效率高于对照组，差异有统计学意义（P<0.05）。
治疗前，两组空腹血糖、餐后2 h血糖、糖化血红蛋白比较，差异无统计学意义（P均>0.05）；治疗后，两组血糖水平低于治疗前，且观察组各指标数值低于对照组，差异有统计学意义（P均<0.05）。
治疗前，两组双歧杆菌、肠杆菌、乳酸杆菌、肠球菌水平比较，差异无统计学意义（P均>0.05）；治疗后，两组双歧杆菌、乳酸杆菌水平高于治疗前，肠杆菌、肠球菌低于治疗前，且观察组双歧杆菌、乳酸杆菌水平高于对照组，肠杆菌、肠球菌水平低于对照组，差异有统计学意义（P均<0.05）。
结论让糖尿病性腹泻患者服用达格列净以及双歧杆菌三联活菌，疗效显著，可调节患者肠道菌群，改善患者血糖水平。
[关键词] 达格列净；双歧杆菌三联活菌；糖尿病性腹泻；疗效；血糖[中图分类号] R587.1 [文献标识码] A [文章编号] 1672-4062（2024）01（a）-0005-04Effect of Dapagliflozin Combined with Bifidobacterium Trifidum on the Efficacy of Diabetic Diarrhea Patients and Blood Glucose LevelsXIE Yongxiu1, ZHANG Xiangrong2, ZHANG Xiulin11.Department of Endocrinology, Ninghua County General Hospital, Sanming, Fujian Province, 365400 China;2.De⁃partment of Gastroenterology, Ninghua County General Hospital, Sanming, Fujian Province, 365400 China[Abstract] Objective To investigate the clinical utility of dapagliflozin combined with bifidobacterium trifidum in the treatment of diabetic diarrhea. Methods A total of 80 patients with diabetic diarrhea admitted to Ninghua County Gen⁃eral Hospital from January 2021 to December 2022 were selected as the study objects, and were divided into control group and observation group according to random number table method, with 40 cases in each group. The control group was treated with metformin + dagaglizin + montmorillonite powder, and the observation group was treated with bifidobacterium triple viable bacteria on this basis. The therapeutic effect, blood glucose level and intestinal flora of the two groups were observed and compared. Results The total effective rate of the observation group was higher than that of the control group, and the difference was statistically significant (P<0.05). Before treatment, there were no sta⁃tistically significant differences in fasting blood glucose, 2-hour postprandial blood glucose and glycated hemoglobin between the two groups (all P>0.05). After treatment, the blood glucose level of the two groups was lower than before treatment, and the value of each index in the observation group was lower than that in the control group, and the differ⁃ences were statistically significant (all P<0.05). Before treatment, there was no statistically significant difference in the [基金项目]福建中医药大学校管科研课题（XB2021180）[作者简介]谢永秀（1988-），女，本科，主治医师，研究方向为内分泌。
白血病新药达沙替尼
白血病新药达沙替尼达沙替尼简介：通用名称：达沙替尼片商品名称：施达赛，SPRYCEL英文名称：Dasatinib Capsules汉语拼音：DashatiniPian成分：本品主要成分为达沙替尼，化学名称为：N-（2-氯-6甲基苯基）-2（{6-[4-（2-羟基乙基）哌嗪基-1]-2-甲基嘧啶基-4}氨基）-1,3-噻唑-5-酰胺-水合物。
化学结构式：分子式：C22H26ClN2O2S·H2O分子量：488.01（无水游离基）；506.02（水合物）临床应用：达沙替尼（Dasatinib/Sprycel），用于已经治疗，包括甲磺酸伊马替尼（Imatinibmesylate/Gleevec）耐药或不能耐受的慢性骨髓性白血病所有病期（慢性期、加速期、淋巴系细胞急变期和髓细胞急变期）的成人患者。
同时，FDA也经正常程序批准达沙替尼治疗对其他疗法耐药或不能耐受的费城染色体阳性的急性淋巴细胞性白血病成人患者。
达沙替尼属多酪氨酸激酶抑制剂，此次主要是依据来自总计包括911例患者的4项国际性、多中心Ⅱ期试验的安全性和疗效结果及其他支持性数据而获准用于上述两适应证的。
它在临床研究中最常报告的副反应有体液潴留、胃肠道症状和出血事件等；最常报告的严重副反应是发热、胸膜积液、发热性中性白)用于粒细胞白血病(CML)6月29日，FDA批准了百时美施贵宝的Sprycel(dasatinib)用于成年患者，治疗两种新的适应症：对伊马替尼等一线药物化疗不敏感的各期慢性粒细胞白血病(CML)，以及对其他疗法无效或不能耐受的Ph染色体阳性的急性淋巴细胞白血病(ALL)。
在已批准上市的药物中，Sprycel是第一种能够抑制多种构型酪氨酸蛋白激酶Abl的口服化疗药。
在纳摩尔浓度，该药能抑制Bcr-Abl, SRC 激酶家族(SRC, LCK, YES, FYN), c-KIT, EPHA2, 和PDGFR-B等多种激酶。
通过抑制上述激酶的作用，Sprycel可抑制CML和Ph+ ALL骨髓中白血病细胞的增殖，但正常红细胞、白细胞和血小板仍可继续增殖。
阿达玛斯氨基酸缩合剂目录大全
1g 5g 25g 100g 1g 5g 25g 5g 25g 1g 5g 25g 1g 5g 25g 100g 5g 25g 100g 25g 100g 250g 1g 5g 25g 100g 250g 500g 5g 25g 100g 1g 5g
￥ 63 ￥ 174 ￥ 558 ￥1,823 ￥ 107 ￥ 236 ￥ 708 ￥ 126 ￥ 378 ￥ 183 ￥ 568 ￥1,712 ￥ 47 ￥ 54 ￥ 103 ￥ 311 ￥ 84 ￥ 239 ￥ 823 ￥ 59 ￥ 103 ￥ 189 ￥ 236 ￥ 708 ￥ 53 ￥ 78 ￥ 128 ￥ 256 ￥ 49 ￥ 66 ￥ 129 ￥ 55 ￥ 116
01141174 01141175 01141176 01271116 01001654 01198120 01198121 01162716 01197860 01004592 01004593 01004594 01004949 01004950 01004951 01004952 01009072 01009073 01009074 01009118 01009119 01009120 01010355 01220437 01014114 01014115 01014116 01271108 01014892 01014893 01014894 01014898 01014901
102368A 102368B 102368C 102368D 10812A 10812B 10812C 110469A 110469B 12581A 12581B 12581C 12771A 12771B 12771C 12771D 14750A 14750B 14750C 14766A 14766B 14766C 15513A 15513B 18159A 18159B 18159C 18159D 18643A 18643B 18643C 18644A 18644B
乙酰胆碱酯酶抑制剂
上海应用技术学院研究生课程《高等天然产物化学》试卷2014 / 2015 学年第1 学期课程代码：NX0702013论文题目：乙酰胆碱酯酶抑制剂的研究进展姓名：芮银146061414康满满146061409专业：制药工程学院：化工学院乙酰胆碱酯酶抑制剂的研究进展芮银，陈祎桐，康满满摘要：本文阐述了乙酰胆碱酯酶抑制剂(AChEI)的研究进展，介绍了用于药物治疗的乙酰胆碱酯酶抑制剂的各种来源如植物、微生物等，及其抑制乙酰胆碱的活性物质。
在此基础上，总结了几种现代分析技术，对AChEIs进行筛选，大大加快AD药物资源的开发利用进程。
这些方法主要有基于比色法的Ellman's法及相关的改进方法、薄层显色法、荧光显色法、电喷雾质谱法等。
但是，到目前为止，现代分析技术在AD药物资源中的应用还处在起步阶段。
关键词：乙酰胆碱酯酶抑制剂，筛选方法，薄层显色法，荧光显色法The progress of acetylcholinesteraseinhibitorsRui Yin, Chen Yitong, Kang ManmanAbstract：In this artical, the research elaborates progress of acetylcholinesterase inhibitors (AChEI), and introduces a variety of sources for drug treatment acetylcholinesterase inhibitors such as plants, microorganisms, and its active ingredients. On this basis, the review summarizes several modern analytic techniques such as Ellman's method which based on the colorimetric method, TLC chromogenic method, fluorescent color method, Electrospray ionization mass spectrometry and so on. However, at present, the application of modern analytic techniques in AD drug resources is still in infancy.Key word: Acetylcholinesterase inhibitors, Screening Methods, TLC chromogenic method, Fluorescent color method目录摘要.................................................................................................错误!未定义书签。
一种在肠道降低人体胆固醇的菌株及制剂[发明专利]
![一种在肠道降低人体胆固醇的菌株及制剂[发明专利]](https://img.taocdn.com/s3/m/b911d76602d276a201292e0c.png)
专利名称：一种在肠道降低人体胆固醇的菌株及制剂专利类型：发明专利
发明人：康白
申请号：CN97101304.7
申请日：19970102
公开号：CN1186855A
公开日：
19980708
专利内容由知识产权出版社提供
摘要：本发明涉及用于降低高胆固醇血症的屎链球菌和含有该菌株活菌的微生态制剂。
屎链球菌(S.faecium)DM891129菌株就是由人体内正常微生物中优选出来的,在生长过程中能分泌出一种由多糖、蛋白质和核糖核酸构成的物质,这些物质可促进胆固醇分解代谢,使其转变成胆汁酸,从而降低胆固醇水平。
经稳定性及各种毒性试验证明,该菌无毒副作用,且具有遗传的稳定性。
申请人：大连医科大学科达药业有限公司
地址：116024 辽宁省大连市高新技术园区科达路9号
国籍：CN
代理机构：大连智慧专利事务所
代理人：周志舰
更多信息请下载全文后查看。
高效液相色谱法测定通便宁胶囊中大黄酸的含量
高效液相色谱法测定通便宁胶囊中大黄酸的含量
澜兰·艾则;布爱洁尔·阿不来提;翟科峰
【期刊名称】《新疆医科大学学报》
【年(卷),期】2008(031)012
【摘要】目的:建立测定通便宁胶囊中大黄酸含量的高效液相色谱法.方法:采用KromassilC18(5 μm,250 mm×4.6 mm),以甲醇-0.1%磷酸溶液(83∶17)为流动相,检测波长为431 nm,柱温为30℃,流速为1 ml/min,进样量10 μl.结果:大黄酸在2.429～ 12.147 μg/ml间呈良好的线性关系(r=0.999 8, n=5),平均回收率为98.75%(n=6).结论:建立的定量方法操作简单、精密度高、重现性好,是控制通便宁胶囊质量的有效方法.
【总页数】3页(P1681-1683)
【作者】澜兰·艾则;布爱洁尔·阿不来提;翟科峰
【作者单位】新疆医科大学第一附属医院药剂科,新疆,乌鲁木齐,830011;新疆乌鲁木齐市中医院,新疆,乌鲁木齐,830000;宿州学院化学与生命科学系,安徽,宿
州,234000
【正文语种】中文
【中图分类】R975;R927.2
【相关文献】
1.高效液相色谱法测定通便灵胶囊中大黄酸的含量 [J], 周友华;包淑英;黄振宇;李凤阁
2.HPLC法测定通便灵胶囊中大黄酸的含量 [J], 党秋萍;刘建峰;张红
3.反相高效液相色谱法测定通便灵胶囊中大黄酸的含量 [J], 韩来敏;王栋;林燕
4.高效液相色谱法测定复方粉刺平胶囊中大黄酸含量 [J], 殷杰;张卫萍
5.高效液相色谱法测定胃欣舒胶囊中大黄酸、大黄素和大黄酚的含量 [J], 高宇明;曾锐
因版权原因，仅展示原文概要，查看原文内容请购买。